ENOV ENOVIS CORPORATION

Enovis Introduces DynaNail Helix™ – a New Twist on Hindfoot Fusions

Enovis Introduces DynaNail Helix™ – a New Twist on Hindfoot Fusions

Designed with our patented and proven NiTiNOL technology, DynaNail Helix™ revolutionizes dynamic compression in foot & ankle fusion

Wilmington, DE, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announces the introduction of the DynaNail Helix™, the latest addition to the DynaNail® family and Enovis’ expansive suite of foot and ankle products. DynaNail Helix is designed to achieve sustained dynamic compression for subtalar fusion with an innovative, anatomically friendly design and simple, screw-like insertion.

Leveraging the same groundbreaking NiTiNOL compressive element technology from other DynaNail systems, the DynaNail Helix is smaller, easy to use, and comes with expanded indications.

“This is the same NiTiNOL technology used in the DynaNail intramedullary system. It provides sustained compression across the fusion site, which traditional screws cannot do,” said Dr. Christopher Hirosei, a foot and ankle orthopedic surgeon based in Boise, Idaho. “The Enovis DynaNail Helix NiTiNOL implants are as easy to use as traditional screws.” 

DynaNail Helix’s NiTiNOL compressive element comes pre-stretched and pre-loaded on a disposable nail guide for maximum efficiency. Like a screw, its threads allow for easy insertion. There are no transverse screws, eliminating the need for orthopedic surgeons to stretch the compressive element manually.

“The flexible, pseudo elastic NiTiNOL element that DynaNail Helix offers is unlike typical static fixation devices that are available on the market. Not only does DynaNail Helix offer intraoperative manual compression, but it also allows for up to 4mm of post-operative compression in response to bone resorption or settling,” said Gary Justak, President of Enovis Foot & Ankle. “This sustained compression is designed to give patients a better chance at healing faster, with fewer complications.”

The DynaNail Helix is one of several new products introduced by Enovis Foot & Ankle this year with active, adaptive healing technology designed to improve patient outcomes across the continuum of care.

For more information on the new DynaNail Helix, visit .

About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit .

MK-10295






i Dr. Hirose is a paid consultant at Enovis.



Attachment



Media Contact:
Megan Foltz
Enovis
(609) 680-0996
 
EN
17/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31...

 PRESS RELEASE

Enovis Announces Fourth Quarter and Full Year 2025 Results

Enovis Announces Fourth Quarter and Full Year 2025 Results Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. ...

 PRESS RELEASE

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health,...

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, UT. About Enovis Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solution...

 PRESS RELEASE

Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Ca...

Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th Dallas, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2025 financial results on Thursday, February 26th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Eno...

 PRESS RELEASE

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Confer...

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m. PST (7:30 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company’s website () at...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch